Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Rituximab Combined With ESHAP in Patients With Relapse or Refractory DLBCL

NCT00568815 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT00568815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00568815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Rituximab Combined With ESHAP in Patients With Relapse or Refractory DLBCL
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2007
Completion date
December 31, 2010
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma